Effects  ||| S:0 E:8 ||| NNS
of  ||| S:8 E:11 ||| IN
dioscorea  ||| S:11 E:21 ||| JJ
modified  ||| S:21 E:30 ||| JJ
pill  ||| S:30 E:35 ||| NN
on  ||| S:35 E:38 ||| IN
cognitive  ||| S:38 E:48 ||| JJ
impairment  ||| S:48 E:59 ||| NN
of  ||| S:59 E:62 ||| IN
patients  ||| S:62 E:71 ||| NNS
with  ||| S:71 E:76 ||| IN
VCIND ||| S:76 E:81 ||| NNP
:  ||| S:81 E:83 ||| :
an  ||| S:83 E:86 ||| DT
preliminary  ||| S:86 E:98 ||| JJ
study  ||| S:98 E:104 ||| NN
of  ||| S:104 E:107 ||| IN
proton  ||| S:107 E:114 ||| JJ
magnetic  ||| S:114 E:123 ||| JJ
resonance  ||| S:123 E:133 ||| NN
spectroscopy  ||| S:133 E:146 ||| NN
To  ||| S:146 E:149 ||| TO
explore  ||| S:149 E:157 ||| VB
the  ||| S:157 E:161 ||| DT
therapeutic  ||| S:161 E:173 ||| JJ
effect  ||| S:173 E:180 ||| NN
evaluation  ||| S:180 E:191 ||| NN
of  ||| S:191 E:194 ||| IN
proton  ||| S:194 E:201 ||| JJ
magnetic  ||| S:201 E:210 ||| JJ
resonance  ||| S:210 E:220 ||| NN
spectroscopy  ||| S:220 E:233 ||| NNS
( ||| S:233 E:234 ||| -LRB-
( ||| S:234 E:235 ||| -LRB-
1 ||| S:235 E:236 ||| LS
) ||| S:236 E:237 ||| -RRB-
H-MRS ||| S:237 E:242 ||| NNP
)  ||| S:242 E:244 ||| -RRB-
in  ||| S:244 E:247 ||| IN
patients  ||| S:247 E:256 ||| NNS
with  ||| S:256 E:261 ||| IN
vascular  ||| S:261 E:270 ||| JJ
cognitive  ||| S:270 E:280 ||| NNS
impairment  ||| S:280 E:291 ||| VBP
no  ||| S:291 E:294 ||| DT
dementia  ||| S:294 E:303 ||| NN
( ||| S:303 E:304 ||| -LRB-
VCIND ||| S:304 E:309 ||| NNP
)  ||| S:309 E:311 ||| -RRB-
with  ||| S:311 E:316 ||| IN
dioscorea  ||| S:316 E:326 ||| JJ
modified  ||| S:326 E:335 ||| JJ
pill ||| S:335 E:339 ||| NN
.  ||| S:339 E:341 ||| .
A  ||| S:341 E:343 ||| DT
total  ||| S:343 E:349 ||| NN
of  ||| S:349 E:352 ||| IN
100  ||| S:352 E:356 ||| CD
patients  ||| S:356 E:365 ||| NNS
with  ||| S:365 E:370 ||| IN
VCIND  ||| S:370 E:376 ||| NNP
were  ||| S:376 E:381 ||| VBD
randomly  ||| S:381 E:390 ||| RB
assigned  ||| S:390 E:399 ||| VBN
into  ||| S:399 E:404 ||| IN
the  ||| S:404 E:408 ||| DT
dioscorea  ||| S:408 E:418 ||| JJ
modified  ||| S:418 E:427 ||| JJ
pill  ||| S:427 E:432 ||| NN
group  ||| S:432 E:438 ||| NN
( ||| S:438 E:439 ||| -LRB-
n  ||| S:439 E:441 ||| CD
=  ||| S:441 E:443 ||| SYM
50 ||| S:443 E:445 ||| CD
)  ||| S:445 E:447 ||| -RRB-
and  ||| S:447 E:451 ||| CC
the  ||| S:451 E:455 ||| DT
aricept  ||| S:455 E:463 ||| JJ
group  ||| S:463 E:469 ||| NN
( ||| S:469 E:470 ||| -LRB-
n  ||| S:470 E:472 ||| CD
=  ||| S:472 E:474 ||| SYM
50 ||| S:474 E:476 ||| CD
) ||| S:476 E:477 ||| -RRB-
.  ||| S:477 E:479 ||| .
And  ||| S:479 E:483 ||| CC
50  ||| S:483 E:486 ||| CD
healthy  ||| S:486 E:494 ||| JJ
volunteers  ||| S:494 E:505 ||| NNS
were  ||| S:505 E:510 ||| VBD
recruited  ||| S:510 E:520 ||| VBN
as  ||| S:520 E:523 ||| IN
normal  ||| S:523 E:530 ||| JJ
group ||| S:530 E:535 ||| NN
.  ||| S:535 E:537 ||| .
Each  ||| S:537 E:542 ||| DT
patient  ||| S:542 E:550 ||| NN
was  ||| S:550 E:554 ||| VBD
examined  ||| S:554 E:563 ||| VBN
with  ||| S:563 E:568 ||| IN
( ||| S:568 E:569 ||| -LRB-
1 ||| S:569 E:570 ||| LS
) ||| S:570 E:571 ||| -RRB-
H-MRS  ||| S:571 E:577 ||| JJ
and  ||| S:577 E:581 ||| CC
scored  ||| S:581 E:588 ||| VBD
with  ||| S:588 E:593 ||| IN
mini-mental  ||| S:593 E:605 ||| JJ
state  ||| S:605 E:611 ||| NN
examination  ||| S:611 E:623 ||| NN
( ||| S:623 E:624 ||| -LRB-
MMSE ||| S:624 E:628 ||| NNP
)  ||| S:628 E:630 ||| -RRB-
and  ||| S:630 E:634 ||| CC
clinical  ||| S:634 E:643 ||| JJ
dementia  ||| S:643 E:652 ||| NN
rating  ||| S:652 E:659 ||| NN
( ||| S:659 E:660 ||| -LRB-
CDR ||| S:660 E:663 ||| NNP
)  ||| S:663 E:665 ||| -RRB-
scale  ||| S:665 E:671 ||| NN
pre-  ||| S:671 E:676 ||| NN
and  ||| S:676 E:680 ||| CC
post-treatment ||| S:680 E:694 ||| JJ
.  ||| S:694 E:696 ||| .
After  ||| S:696 E:702 ||| IN
therapy ||| S:702 E:709 ||| NN
,  ||| S:709 E:711 ||| ,
the  ||| S:711 E:715 ||| DT
NAA ||| S:715 E:718 ||| NNP
/ ||| S:718 E:719 ||| NNP
Cr  ||| S:719 E:722 ||| NNP
ratios  ||| S:722 E:729 ||| NNS
and  ||| S:729 E:733 ||| CC
the  ||| S:733 E:737 ||| DT
itemized  ||| S:737 E:746 ||| JJ
scores  ||| S:746 E:753 ||| NNS
of  ||| S:753 E:756 ||| IN
cognitive  ||| S:756 E:766 ||| JJ
scale  ||| S:766 E:772 ||| NN
compared  ||| S:772 E:781 ||| VBN
with  ||| S:781 E:786 ||| IN
that  ||| S:786 E:791 ||| DT
of  ||| S:791 E:794 ||| IN
pre-therapy  ||| S:794 E:806 ||| NNP
had  ||| S:806 E:810 ||| VBD
significantly  ||| S:810 E:824 ||| RB
difference  ||| S:824 E:835 ||| NN
( ||| S:835 E:836 ||| -LRB-
P  ||| S:836 E:838 ||| NNP
< ||| S:838 E:840 ||| SYM
0.05 ||| S:840 E:844 ||| CD
)  ||| S:844 E:846 ||| -RRB-
in  ||| S:846 E:849 ||| IN
the  ||| S:849 E:853 ||| DT
dioscorea  ||| S:853 E:863 ||| JJ
modified  ||| S:863 E:872 ||| JJ
pill  ||| S:872 E:877 ||| NN
group  ||| S:877 E:883 ||| NN
( ||| S:883 E:884 ||| -LRB-
MMSE  ||| S:884 E:889 ||| NNP
( ||| S:889 E:890 ||| -LRB-
26.5  ||| S:890 E:895 ||| CD
±  ||| S:895 E:897 ||| CD
2.0 ||| S:897 E:900 ||| CD
) ||| S:900 E:901 ||| -RRB-
,  ||| S:901 E:903 ||| ,
CDR ||| S:903 E:906 ||| NNP
( ||| S:906 E:907 ||| -LRB-
0.14  ||| S:907 E:912 ||| CD
±  ||| S:912 E:914 ||| CD
0.23 ||| S:914 E:918 ||| CD
) ||| S:918 E:919 ||| -RRB-
) ||| S:919 E:920 ||| -RRB-
vs ||| S:920 E:922 ||| NNS
( ||| S:922 E:923 ||| -LRB-
MMSE ||| S:923 E:927 ||| NNP
( ||| S:927 E:928 ||| -LRB-
25.1  ||| S:928 E:933 ||| CD
±  ||| S:933 E:935 ||| CD
2.3 ||| S:935 E:938 ||| CD
) ||| S:938 E:939 ||| -RRB-
,  ||| S:939 E:941 ||| ,
CDR ||| S:941 E:944 ||| NNP
( ||| S:944 E:945 ||| -LRB-
0.5 ||| S:945 E:948 ||| CD
) ||| S:948 E:949 ||| -RRB-
) ||| S:949 E:950 ||| -RRB-
.  ||| S:950 E:952 ||| .
But  ||| S:952 E:956 ||| CC
no  ||| S:956 E:959 ||| DT
difference  ||| S:959 E:970 ||| NN
existed  ||| S:970 E:978 ||| VBD
in  ||| S:978 E:981 ||| IN
the  ||| S:981 E:985 ||| DT
aricept  ||| S:985 E:993 ||| JJ
group  ||| S:993 E:999 ||| NN
( ||| S:999 E:1000 ||| -LRB-
P  ||| S:1000 E:1002 ||| NNP
>  ||| S:1002 E:1004 ||| CD
0.05 ||| S:1004 E:1008 ||| CD
) ||| S:1008 E:1009 ||| -RRB-
.  ||| S:1009 E:1011 ||| .
( ||| S:1011 E:1012 ||| -LRB-
1 ||| S:1012 E:1013 ||| LS
) ||| S:1013 E:1014 ||| -RRB-
H-MRS  ||| S:1014 E:1020 ||| NNP
may  ||| S:1020 E:1024 ||| MD
objectively  ||| S:1024 E:1036 ||| RB
reflect  ||| S:1036 E:1044 ||| VB
cognitive  ||| S:1044 E:1054 ||| JJ
dysfunction  ||| S:1054 E:1066 ||| NN
in  ||| S:1066 E:1069 ||| IN
VCIND  ||| S:1069 E:1075 ||| NNP
patients ||| S:1075 E:1083 ||| NNS
.  ||| S:1083 E:1085 ||| .
And  ||| S:1085 E:1089 ||| CC
it  ||| S:1089 E:1092 ||| PRP
has  ||| S:1092 E:1096 ||| VBZ
important  ||| S:1096 E:1106 ||| JJ
values  ||| S:1106 E:1113 ||| NNS
in  ||| S:1113 E:1116 ||| IN
the  ||| S:1116 E:1120 ||| DT
therapeutic  ||| S:1120 E:1132 ||| JJ
effect  ||| S:1132 E:1139 ||| NN
evaluation  ||| S:1139 E:1150 ||| NN
of  ||| S:1150 E:1153 ||| IN
VCIND  ||| S:1153 E:1159 ||| NNP
with  ||| S:1159 E:1164 ||| IN
dioscorea  ||| S:1164 E:1174 ||| JJ
modified  ||| S:1174 E:1183 ||| JJ
pill ||| S:1183 E:1187 ||| NN
.  ||| S:1187 E:1189 ||| .
